Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


MANNING MARTHA E Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/30/2023 4 MANNING MARTHA E (VP, GEN. COUNSEL & CORP. SEC.) has filed a Form 4 on MARINUS PHARMACEUTICALS, INC.
Txns: Granted 16,548 shares @ $0
Granted 74,468 options to buy @ $5.94, valued at $442.3k
05/26/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/07/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/19/2021 4 MANNING MARTHA E (VP Gen Counsel and Corp Sec.) has filed a Form 4 on MARINUS PHARMACEUTICALS INC
Txns: Granted 57,500 options to buy @ $12.6, valued at $724.5k
06/17/2020 4 MANNING MARTHA E (VP, Gen. Counsel & Corp. Sec.) has filed a Form 4 on MARINUS PHARMACEUTICALS INC
Txns: Granted 300,000 options to buy @ $2.52, valued at $756k
06/17/2020 3 MANNING MARTHA E (VP, Gen. Counsel & Corp. Sec.) has filed a Form 3 on MARINUS PHARMACEUTICALS INC
01/29/2020 4 MANNING MARTHA E (General Counsel) has filed a Form 4 on ACHILLION PHARMACEUTICALS INC
Txns: Disposed/sold 2,500 shares @ $6.3, valued at $15.8k
Disposed/sold 215,000 options to buy @ $2.9, valued at $623.5k
Disposed/sold 150,000 options to buy @ $2.18, valued at $327k
Disposed/sold 110,000 options to buy @ $6.79, valued at $746.9k
Disposed/sold 135,000 options to buy @ $4.11, valued at $554.9k
01/25/2019 4 MANNING MARTHA E (General Counsel) has filed a Form 4 on ACHILLION PHARMACEUTICALS INC
Txns: Granted 150,000 options to buy @ $2.18, valued at $327k
02/13/2018 4 MANNING MARTHA E (General Counsel) has filed a Form 4 on ACHILLION PHARMACEUTICALS INC
Txns: Granted 215,000 options to buy @ $2.9, valued at $623.5k
01/19/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
12/05/2016 4 Form 4 - Statement of changes in beneficial ownership of securities

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy